Artur Machlenkin

Director Técnico/Científico/I+D en PLURI INC. .

Health Technology

Consumer Services

Commercial Services

Perfil

Artur Machlenkin is currently Chief Scientific Officer at Pluri, Inc. since 2023.
Formerly, Dr. Machlenkin was Chief Executive Officer at Pantheon Biosciences Ltd. from 2017 to 2021 and held the position of Head-Immuno Oncology at Compugen USA, Inc. Education includes a doctorate from the Weizmann Institute of Science.

Cargos activos de Artur Machlenkin

Empresas	Cargo	Inicio
PLURI INC.	Director Técnico/Científico/I+D	01/05/2022

Todos los cargos activos de Artur Machlenkin

Antiguos cargos conocidos de Artur Machlenkin.

Empresas	Cargo	Fin
Pantheon Biosciences Ltd. Pantheon Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Develops molecular therapies and tools	Director Ejecutivo	01/09/2021
Compugen Usa, Inc. Compugen Usa, Inc. The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Artur Machlenkin.

Formación de Artur Machlenkin.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Artur Machlenkin.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	4
Pluri, Inc. Pluri, Inc. BiotechnologyHealth Technology Develops placenta-based cell therapy products for the treatment of muscle trauma and hematological disorders, radiation damage and inflammation	Health Technology
Weizmann Institute of Science Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Compugen Usa, Inc. Compugen Usa, Inc. The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies.
Pantheon Biosciences Ltd. Pantheon Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Develops molecular therapies and tools	Commercial Services